Introduction {#tca12889-sec-0001}
============

HER2 alterations, including gene amplification, protein overexpression, and mutation, have been implicated as oncogenic drivers in lung cancers. HER2 amplification is identified as a resistance mechanism that occurs independently of *EGFR* T790M mutations,[1](#tca12889-bib-0001){ref-type="ref"}, [2](#tca12889-bib-0002){ref-type="ref"} while HER2 mutations are thought to play a more significant role in lung tumorigenesis than overexpression or gene amplification, with promising efficacy of HER2 inhibitors.[3](#tca12889-bib-0003){ref-type="ref"} In this study, we describe the case of a patient who progressed on first‐generation EGFR‐TKIs and developed an *EGFR* T790M mutation, HER2 amplification, and HER2 mutation but achieved a remarkable response after combination treatment with osimertinib and afatinib.

Case report {#tca12889-sec-0002}
-----------

A 57‐year‐old male smoker (40 pack‐year) presented with a dry cough. A computed tomography (CT) scan revealed a mass in the inferior lobe of the right lung and multiple metastases in both sides. A bone scan also showed multiple metastases. A biopsy showed a lung adenocarcinoma. Biomarker analysis via Ventana immunohistochemistry and amplification refractory mutation system (ARMS) was negative for *ALK* rearrangement and exon 21 *EGFR* L858R mutation, respectively. First‐line icotinib was commenced in April 2016 and a partial response was achieved until March 2017, with progression‐free survival (PFS) of 11 months (Fig [1](#tca12889-fig-0001){ref-type="fig"}a). Liquid biopsy (super‐ARMs) revealed the emergence of a T790M mutation, thus osimertinib was administered in May 2017. The patient experienced shortness of breath after a month of osimertinib treatment, with worsened pleural effusion but reduced lung metastases (Fig [1](#tca12889-fig-0001){ref-type="fig"}b). Next‐generation sequencing (NGS)‐based assay performed on DNA extracted from the pleural effusion and post‐icotinib tumor tissues identified additional HER2 amplification and mutation in exon 20 V777L (Fig [2](#tca12889-fig-0002){ref-type="fig"}), while retrospective NGS showed no HER2 amplification or mutation in the pre‐icotinib specimen. Continuous osimertinib treatment and a pleural injection of cisplatin were administered (Fig [1](#tca12889-fig-0001){ref-type="fig"}c) and a trend of progression was noted. Afatinib (30 mg daily) was added, and the patient achieved a partial response after four weeks of treatment, with mild toxicity (grade 1 rash and grade 2 diarrhea).

![Computed tomography scans taken after (**a**) icotinib treatment showed a primary mass in the right inferior lobe and multiple metastases; (**b**) four weeks of osimertinib treatment showed a stable primary tumor, decreased metastases, and increased pleural effusion; (**c**) four months of osimertinib treatment; and (**d**) one month of combination osimertinib and afatinib treatment revealed a partial response and significantly improved pleural effusion.](TCA-9-1774-g001){#tca12889-fig-0001}

![Next‐generation sequencing readings of *EGFR* mutation, HER2 amplification, and HER2 mutation from post‐icotinib treatment tumor biopsy and pleural effusion samples. (**a**) A list of mutations in the sample. (**b**) The tumor and (**c**) pleural effusion samples show HER2 amplification after icotinib treatment with copy number variations of 11.73 and 2.98, respectively.](TCA-9-1774-g002){#tca12889-fig-0002}

Discussion {#tca12889-sec-0003}
==========

EGFR‐TKIs are recommended as first‐line treatment for non‐small cell lung cancer (NSCLC) patients harboring activating *EGFR* mutations. Despite the remarkable initial response, resistance to TKI eventually occurred in our patient who developed a T790M mutation within exon 20 of the TK domain of *EGFR*, which is the most common mutation.[4](#tca12889-bib-0004){ref-type="ref"} Other mechanisms were also identified, including HER2 amplification, which occurred independently of the *EGFR* T790M.[2](#tca12889-bib-0002){ref-type="ref"} Overlap among mechanisms of acquired resistance has been observed in 4% of 155 patients, and mainly consists of small cell histologic transformation with other mutations; only one patient had evidence of T790M and HER2 amplification in two different samples.[1](#tca12889-bib-0001){ref-type="ref"} In our case, the coexistence of T790M, HER2 amplification, and HER2 mutation was found in both the primary tumor and pleural effusion samples. Furthermore, the metastatic lesions responded to single‐agent osimertinib, as well as the combination of osimertinib and afatinib, suggesting homogeneous resistance mechanisms in the primary tumor and metastatic lesions.

HER2 alterations, including gene amplification, protein overexpression, and mutation, have been implicated as oncogenic drivers in lung cancers. HER2 mutations are present in approximately 2% of NSCLC patients and consist of deletions, insertions, and missense mutations, which are often seen in women and non‐smokers.[5](#tca12889-bib-0005){ref-type="ref"}, [6](#tca12889-bib-0006){ref-type="ref"}, [7](#tca12889-bib-0007){ref-type="ref"}, [8](#tca12889-bib-0008){ref-type="ref"} HER2 mutations are thought to play a more significant role in lung tumorigenesis than overexpression or gene amplification via constitutive activation of the receptor and downstream AKT and MEK pathways.[3](#tca12889-bib-0003){ref-type="ref"} The majority of patients with HER2 amplified lung cancers are male and smokers.[7](#tca12889-bib-0007){ref-type="ref"} Re‐biopsies in 155 patients resistant to EGFR‐TKIs revealed no HER2 mutation, while 13% of patients harbored HER2 amplification,[1](#tca12889-bib-0001){ref-type="ref"} suggesting that HER2 amplification is more significant than mutation in the development of acquired resistance to *EGFR* inhibitors. HER2 amplification and mutation may represent distinct molecular targets; therefore, different therapies are needed.[7](#tca12889-bib-0007){ref-type="ref"} HER2 mutation is predictive of sensitivity to HER2 inhibitors.[3](#tca12889-bib-0003){ref-type="ref"} Several studies and case series have reported responses to afatinib, dacomitinib, and trastuzumab in patients with HER2‐mutant NSCLC,[8](#tca12889-bib-0008){ref-type="ref"}, [9](#tca12889-bib-0009){ref-type="ref"}, [10](#tca12889-bib-0010){ref-type="ref"}, [11](#tca12889-bib-0011){ref-type="ref"}, [12](#tca12889-bib-0012){ref-type="ref"} with the exception of a phase 2 study in which patients with HER2 insertion YVMA failed to respond to dacomitinib.[11](#tca12889-bib-0011){ref-type="ref"} However, for patients with HER2 gene amplification or overexpression, inconsistent efficacy results were observed from HER2‐targeted antibodies, such as trastuzumab.[13](#tca12889-bib-0013){ref-type="ref"}, [14](#tca12889-bib-0014){ref-type="ref"}, [15](#tca12889-bib-0015){ref-type="ref"}

In this study, we present the first case of an overlap of T790M, HER2 amplification, and HER2 mutation. Moreover, HER2 mutation was identified during the development of resistance, suggesting that HER2 mutation may cause resistance to first‐generation EGFR‐TKIs. Our findings raise the question of what biologic mechanisms underlie HER2‐directed resistance. HER2 amplification is a known mechanism of resistance to EGFR‐TKIs; however, a remarkable response was achieved after the addition of afatinib, which has limited activity in HER2‐amplified NSCLC but favorable activity in HER2‐mutant subgroups. More complex mechanisms beyond HER2‐amplification may have contributed to resistance in this patient.

To the best of our knowledge, this is the first time that the HER2 mutation has been detected in an NSCLC patient with acquired resistance to first‐generation EGFR‐TKIs, as well as the overlap of T790M, HER2 amplification, and HER2 mutation. We showed the efficacy of osimertinib and afatinib in overcoming multiple resistance from *EGFR* T790M and HER2 alterations. Greater understanding of how to overcome mechanisms of multiple resistance and the application of combined therapy may help to transform patient outcomes.
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